CAR T-Cell Therapy and Bispecific Antibodies Reshape Treatment Sequencing in Acute Lymphoblastic Leukemia
Clinical Summary:
-
Alexandra Gomez-Arteaga, MD, and Elias Jabbour, MD, examine the evolving treatment landscape for adult acute lymphoblastic leukemia (ALL), including the sequencing of CAR T-cell therapy, bispecific T-cell engagers, and allogeneic stem cell transplantation.
-
Emerging immunotherapy strategies may support earlier CAR T-cell therapy, improved disease control, and reduced reliance on transplantation in selected patients, while measurable residual disease (MRD) status, disease burden, and prior treatment exposure remain important considerations.
-
These developments highlight the importance of individualized treatment sequencing, early referral to specialized centers, and continued clinical investigation to reduce treatment duration, improve accessibility, and optimize outcomes for patients with ALL.
Alexandra Gomez-Arteaga, MD, Weill Cornell Medicine, New York, New York, and Elias Jabbour, MD, MD Anderson Cancer Center, Houston, Texas, discuss the evolving role of CAR T-cell therapy, bispecific antibodies, and allogeneic stem cell transplantation in adult acute lymphoblastic leukemia following their presentations at the Lymphoma, Leukemia & Myeloma Congress in New York, New York.
Dr Gomez-Arteaga and Dr Jabbour review how emerging immunotherapy strategies are reshaping treatment sequencing, including opportunities to introduce CAR T-cell therapy earlier and potentially reduce transplantation needs in selected patients. They also discuss MRD-guided treatment decisions, strategies to reduce disease burden before cellular therapy, and the importance of collaboration between academic and community centers to improve access to advanced treatments.
